A Bayesian mathematical model of motor and cognitive outcomes in Parkinson’s disease

• Boris Hayete,

  Affiliation GNS Healthcare, Cambridge, Massachusetts, United States of America

  ⨯
• Diane Wuest,

  Affiliation GNS Healthcare, Cambridge, Massachusetts, United States of America

  ⨯
• Jason Laramie,

  Affiliation Novartis, Cambridge, Massachusetts, United States of America

  ⨯
• Paul McDonagh,

  Affiliation Alexion Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Bruce Church,

  Affiliation GNS Healthcare, Cambridge, Massachusetts, United States of America

  ⨯
• Shirley Eberly,

  Affiliation University of Rochester, Rochester, New York, United States of America

  ⨯
• Anthony Lang,

  Affiliation Morton and Gloria Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada

  ⨯
• Kenneth Marek,

  Affiliation Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States of America

  ⨯
• Karl Runge,

  Affiliation GNS Healthcare, Cambridge, Massachusetts, United States of America

  ⨯
• Ira Shoulson,

  Affiliation Georgetown University, Washington, DC, United States of America

  ⨯
• Andrew Singleton,

  Affiliation National Institute on Aging, NIH, Bethesda, Maryland, United States of America

  ⨯
• Caroline Tanner,

  Affiliation University of San Francisco & San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America

  ⨯
• Iya Khalil,

  Affiliation GNS Healthcare, Cambridge, Massachusetts, United States of America

  ⨯
• Ajay Verma,

  Affiliation Biogen Idec, Cambridge, Massachusetts, United States of America

  ⨯
• Bernard Ravina

  * E-mail: bravina@vygr.com

  Affiliation Voyager Therapeutics, Cambridge, Massachusetts, United States of America

  ⨯